Reply: Glucocorticoid use and skin cancers by Karagas, M R & Nierenberg, D W
Crude odds ratios with accompanying 95% confidence intervals
were calculated to measure the association between risk of BCC
and SCC and oral steroid use (Table 2). Stronger increases in risk
of each skin cancer were found for steroid use to treat
(supposedly) non-atopic conditions, compared to nonusers.
Steroid use to possibly treat atopic conditions was not found to
be associated with either type of cancer. These findings suggest
that the effects of atopic conditions may confound the association
between glucocorticoids and skin cancer risk. The analysis is
limited in that the odds ratios have not been adjusted for other
confounding factors, although the adjusted odds ratios in the
original analysis were very similar in magnitude to the unadjusted
odds ratios. Another limitation involves the fact that four cases
(two BCC, two SCC) that received steroid treatment for conditions
in more than one category were not identified as such in the
original table, and so could not be adjusted for in this analysis.
However, other analyses involving different assumptions about the
possible joint conditions suggested that the findings would not be
greatly influenced by this problem. Both of these issues could be
addressed by the authors through reanalysis of the original study
data. It would also be interesting to know whether a similar
reanalysis of inhaled steroid use resulted in comparable findings.
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Sir,
We appreciate Dr Purdue’s interest in our report on use of
glucocorticoids and skin cancers. As suggested in his letter, we
reclassified indication for steroid use into two categories: (1)
atopic conditions (i.e. ‘respiratory conditions and asthma’ and
‘allergies’) and (2) non-atopic conditions (i.e. ‘musculoskeletal and
connective tissue disease’, ‘neoplasm’, ‘gastrointestinal disease’,
and ‘other condition’) (Table 1). In the reanalysis of the data, we
noted an error in Table 1 of the original report. There were only
two controls that used glucocorticoids for allergies (the seven
controls in the original report included users of inhaled steroids).
The correct numbers appear in Table 1 below and are restricted to
oral users. The odds ratios associated with oral glucocorticoid use,
stratified by Dr Purdue’s classification, are shown in Tables 2
and 3. The results for ‘any use’ differ very slightly from the original
report because we removed individuals with more than one
indication or with missing data on the indication for use for this
reanalysis.
Table 1 Oral glucocorticoid use according to indication among skin
cancer cases and controls
Steroid
use
a Indication
Controls
N (%)
BCC
N (%)
SCC
N (%)
No 491 (95.0) 534 (93.0) 245 (91.1)
Yes Any use
b 26 (5.0) 40 (7.0) 24 (8.9)
Treat possible
atopic conditions
c
11 (2.1) 12 (2.1) 9 (3.4)
Treat possible
non-atopic conditions
d
15 (2.9) 28 (4.9) 15 (5.6)
BCC¼basal cell carcinoma; SCC¼squamous cell carcinoma.
aUse of oral
glucocorticoid use for 1 month or longer.
bExcludes three individuals with more
than one indication (two BCC, one SCC) and two individuals with missing data on
indication for use (one BCC, one SCC).
cIncludes ‘respiratory conditions and asthma’
and ‘allergies’.
dIncludes ‘musculoskeletal and connective tissue disease’, ‘neoplasm’,
‘gastrointestinal disease’, ‘other condition’.
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his hypothesis, that is, the association may be limited to non-
atopic conditions (Table 2). However, lack of precision in our risk
estimates prevents us from drawing any firm conclusions. In our
original report, the association was stronger for squamous cell
carcinomas (SCC), and for this cell type, the risk associated with
oral glucocorticoid use does not differ much by type of condition
(Table 3). Unfortunately, we were unable to perform the
recommended analysis of inhaled steroid use since the indications
for use almost exclusively fell into the atopic category (Table 4).
The potential effect of immune response and immunosuppression
on the incidence of skin cancer is of considerable interest to us.
We hope that further studies will address commonly used
immune-modulating drugs along with atopic conditions, and
that this, in turn, will shed light on this pathway to human
malignancies.
Table 2 Association between oral glucocorticoid use and BCC, with
further analysis by indication
BCC BCC
Steroid Crude Age, sex adjusted
use
a Indication OR (95% CI) OR (95% CI)
No 1.00 (reference) 1.00 (reference)
Yes Any use
b 1.45 (0.87, 2.41) 1.43 (0.86, 2.38)
Treat possible
atopic conditions
c
1.00 (0.44, 2.29) 0.97 (0.42, 2.23)
Treat possible
non-atopic conditions
d
1.72 (0.91, 3.25) 1.70 (0.90, 3.24)
BCC¼basal cell carcinoma; OR¼odds ratio; CI¼confidence interval.
aUse of oral
glucocorticoid use for 1 month or longer.
bExcludes two cases with more than one
indication and one case with missing data on indication for use.
cIncludes ‘respiratory
conditions and asthma’ and ‘allergies’.
dIncludes ‘musculoskeletal and connective tissue
disease’, ‘neoplasm’, ‘gastrointestinal disease’, ‘other condition’.
Table 3 Association between oral glucocorticoid use and SCC, with further analysis by indication
SCC SCC SCC
Crude Age, sex adjusted Age, sex, skin type
b adjusted
Steroid use
a Indication OR (95% CI) OR (95% CI) OR (95% CI)
No — — —
Yes Any use
c 1.93 (1.09, 3.41) 1.98 (1.10, 3.57) 2.21 (1.21, 4.04)
Treat possible atopic conditions
d 1.64 (0.67, 4.01) 1.68 (0.67, 4.19) 1.75 (0.68, 4.46)
Treat possible non-atopic conditions
e 2.00 (0.96, 4.17) 2.10 (0.99, 4.47) 2.49 (1.16, 5.36)
SCC¼squamous cell carcinoma; OR¼odds ratio; CI¼confidence interval.
aUse of oral glucocorticoid use for 1 month or longer.
bSkin reaction to sun exposure.
cExcludes one
case with more than one indication and one case with missing data on indication for use.
dIncludes ‘respiratory conditions and asthma’ and ‘allergies’.
eIncludes ‘musculoskeletal
and connective tissue disease’, ‘neoplasm’, ‘gastrointestinal disease’, ‘other condition’.
Table 4 Indication for glucocorticoid use among those who use inhaled
steroids
Indication for steroid use Inhaled only Inhaled+oral
a
Respiratory conditions and asthma 29 10
Allergy 7 1
Musculoskeletal and connective tissue disease 1 0
Gastrointestinal disease 0 1
Other condition 3 2
aThree people have more than one reason for steroid use.
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